Candel Therapeutics (CADL) Invested Capital (2022 - 2025)

Candel Therapeutics (CADL) has 4 years of Invested Capital data on file, last reported at $4.2 million in Q3 2025.

• For the quarter ending Q3 2025, Invested Capital fell 57.11% year-over-year to $4.2 million; the trailing twelve-month figure through Dec 2025 stood at $20.1 million (down 48.88% YoY), and the FY2024 full-year result was $9.9 million, up 11.27% from the prior year.
• Invested Capital slipped to $4.2 million in Q3 2025, from $6.7 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $20.0 million in Q1 2022 to a low of $1.3 million in Q1 2023.
• A 4-year average of $10.6 million and a median of $9.8 million in 2024 frame the typical range for Invested Capital.
• Across the five-year window, Invested Capital sank 93.74% in 2023 and surged 679.49% in 2024, its largest moves.
• Tracing CADL's Invested Capital over 4 years: stood at $20.0 million in 2022, then tumbled by 55.54% to $8.9 million in 2023, then increased by 11.27% to $9.9 million in 2024, then sank by 57.3% to $4.2 million in 2025.
• Business Quant data shows CADL's Invested Capital at $4.2 million in Q3 2025, $6.7 million in Q2 2025, and $9.2 million in Q1 2025.